GlassScriptPhysician profile
Elizabeth L Brown
NPI 1437496411
$3,640.73
in general payments reported to CMS, 2019-2025
27 companies · $772 in 2025
The $772 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.89 · 2022: $171 · 2023: $1,094 · 2024: $1,583 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,449.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $586.29 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $424.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $302.31 | 2023-2025 | |
| Lilly USA, LLC | $300.10 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Edwards Lifesciences Corporation | $197.97 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.68 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $131.25 | 2023-2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $124.42 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $108.38 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $105.19 | 2023-2024 | Otezla, Repatha |
| Lundbeck LLC | $56.95 | 2022-2025 | Abilify Asimtufii |
| Phathom Pharmaceuticals, INC. | $51.06 | 2025 | Voquezna |
| Astellas Pharma US INC | $49.94 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $46.76 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $46.15 | 2024 | |
| Vanda Pharmaceuticals INC. | $43.93 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $42.86 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $42.51 | 2023 | Heplisav-B |
| Axsome Therapeutics, INC. | $35.72 | 2024-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $23.22 | 2023 | Jornay Pm |
| Abbott Laboratories | $21.82 | 2024 | Freestyle Libre 3 |
| Halozyme INC | $20.00 | 2023 | |
| Chiesi USA, INC. | $19.59 | 2023 | Cleviprex, Kengreal |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.09 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $12.89 | 2023 | |
| Corium, LLC | $12.24 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.